Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA To Release Only Confirmed New Device Risk Data It Sees, Says Final Emerging Signals Guidance

Executive Summary

FDA Dec. 13 issued a final "emerging signals" guidance that includes some significant changes from the draft version released late last year. The update emphasizes that the agency will release to the public only confirmed information that it has seen on adverse events or other negative reports connected to a marketed medical device, which could change the product's risk profile.


Related Content

What US FDA’s ‘Emerging Signals’ Guidance Means For Medical Device Manufacturers
Consumers Groups Praise FDA Draft ‘Emerging Signals’ Plan; Industry Continues Opposition





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts